Soligenix, Inc. (LON:0A6I)
1.240
-0.010 (-0.80%)
At close: Feb 3, 2026
Soligenix Revenue
In the year 2024, Soligenix had annual revenue of $119.37K USD, down -85.78%.
Revenue
$119.37K
Revenue Growth
-85.78%
P/S Ratio
n/a
Revenue / Employee
$7.46K
Employees
16
Market Cap
9.06M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.37K | -719.99K | -85.78% |
| Dec 31, 2023 | 839.36K | -109.55K | -11.55% |
| Dec 31, 2022 | 948.91K | 124.64K | 15.12% |
| Dec 31, 2021 | 824.27K | -1.54M | -65.07% |
| Dec 31, 2020 | 2.36M | -2.27M | -49.04% |
| Dec 31, 2019 | 4.63M | -611.53K | -11.67% |
| Dec 31, 2018 | 5.24M | -191.02K | -3.52% |
| Dec 31, 2017 | 5.43M | -5.02M | -48.01% |
| Dec 31, 2016 | 10.45M | 1.68M | 19.16% |
| Dec 31, 2015 | 8.77M | 1.73M | 24.50% |
| Dec 31, 2014 | 7.04M | 3.82M | 118.45% |
| Dec 31, 2013 | 3.22M | 79.53K | 2.53% |
| Dec 31, 2012 | 3.14M | -4.52M | -58.96% |
| Dec 31, 2011 | 7.66M | 5.72M | 293.44% |
| Dec 31, 2010 | 1.95M | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | 1.26M | -1.06M | -45.61% |
| Dec 31, 2006 | 2.31M | -762.72K | -24.80% |
| Dec 31, 2005 | 3.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caffyns | 271.68M |
| Asia Strategic Holdings | 24.19M |
| abrdn Property Income Trust | 12.59M |
| Nanoco Group | 7.62M |
| London BTC Company | 940.01K |
| Pennpetro Energy | 390.35K |
| IMC Exploration Group | 56.58K |
Soligenix News
- 6 weeks ago - Soligenix (SNGX) Shows Promising Results in Phase 2a Behcet's Disease Study - GuruFocus
- 6 weeks ago - Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) - PRNewsWire
- 6 weeks ago - Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel - Benzinga
- 6 weeks ago - Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel - Benzinga
- 6 weeks ago - Soligenix (SNGX) Reports Promising Phase 2a Results for Psoriasis Treatment - GuruFocus
- 6 weeks ago - Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis - PRNewsWire
- 2 months ago - Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space - GlobeNewsWire
- 2 months ago - Soligenix (SNGX) Completes Key Enrollment for Phase 3 Study on CTCL Treatment - GuruFocus